Eric Lawitz

Summary

Publications

  1. doi request reprint Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics
    Eric Lawitz
    Alamo Medical Research, 621 Camden Street, San Antonio, TX 78215, United States Electronic address
    Antiviral Res 99:214-20. 2013
  2. doi request reprint A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients
    Eric J Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    Antivir Ther 18:311-9. 2013
  3. doi request reprint A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
    Eric J Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    J Hepatol 57:24-31. 2012
  4. pmc Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti
    Matthew J Hepburn
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    BMC Gastroenterol 4:31. 2004
  5. pmc The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study
    Matthew J Hepburn
    Department of Medicine, Brooke Army Medical Center, Fort Sam, Houston, Texas, USA
    BMC Gastroenterol 5:14. 2005
  6. doi request reprint Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
    Eric Lawitz
    Alamo Medical Research, 621 Camden Suite 202, San Antonio, TX 78215, USA
    J Hepatol 49:163-9. 2008
  7. doi request reprint A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
    Eric Lawitz
    The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States
    J Hepatol 59:18-23. 2013
  8. doi request reprint Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    Eric Lawitz
    Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX, USA Electronic address
    Lancet 383:515-23. 2014
  9. doi request reprint A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment
    Eric Lawitz
    Alamo Medical Research, San Antonio, TX, United States
    J Hepatol 59:11-7. 2013
  10. doi request reprint Sofosbuvir for previously untreated chronic hepatitis C infection
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX 78215, USA
    N Engl J Med 368:1878-87. 2013

Detail Information

Publications20

  1. doi request reprint Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics
    Eric Lawitz
    Alamo Medical Research, 621 Camden Street, San Antonio, TX 78215, United States Electronic address
    Antiviral Res 99:214-20. 2013
    ..Further development of vaniprevir, including studies in combination with other anti-HCV agents, is ongoing...
  2. doi request reprint A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients
    Eric J Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    Antivir Ther 18:311-9. 2013
    ..GS-9451 is a novel inhibitor of the HCV NS3/4A protease and demonstrates potent in vitro suppression of HCV genotype 1 replicons...
  3. doi request reprint A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
    Eric J Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    J Hepatol 57:24-31. 2012
    ..The safety, tolerability, pharmacokinetics, antiviral activity, and resistance profile of once-daily GS-5885 doses of 1-90 mg were evaluated in patients with chronic genotype 1 HCV...
  4. pmc Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti
    Matthew J Hepburn
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    BMC Gastroenterol 4:31. 2004
    ..The purpose of this investigation was to determine the seroprevalence of hepatitis C and associated risk factors in an urban population in Haiti...
  5. pmc The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study
    Matthew J Hepburn
    Department of Medicine, Brooke Army Medical Center, Fort Sam, Houston, Texas, USA
    BMC Gastroenterol 5:14. 2005
    ..Our hypothesis was ultrasonography would perform poorly for the detection of steatosis outside of the context of a controlled study, primarily due to false-positive results caused by hepatic fibrosis and inflammation...
  6. doi request reprint Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
    Eric Lawitz
    Alamo Medical Research, 621 Camden Suite 202, San Antonio, TX 78215, USA
    J Hepatol 49:163-9. 2008
    ..This study assessed the safety and antiviral effects of telaprevir (VX-950) in combination with peginterferon alfa-2a and ribavirin...
  7. doi request reprint A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
    Eric Lawitz
    The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States
    J Hepatol 59:18-23. 2013
    ....
  8. doi request reprint Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    Eric Lawitz
    Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX, USA Electronic address
    Lancet 383:515-23. 2014
    ....
  9. doi request reprint A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment
    Eric Lawitz
    Alamo Medical Research, San Antonio, TX, United States
    J Hepatol 59:11-7. 2013
    ....
  10. doi request reprint Sofosbuvir for previously untreated chronic hepatitis C infection
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX 78215, USA
    N Engl J Med 368:1878-87. 2013
    ..In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection...
  11. doi request reprint Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study
    Daniel E Brady
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    Clin Gastroenterol Hepatol 8:66-71.e1. 2010
    ..Induction therapy with higher doses of PEG interferon may improve first-phase viral kinetics and thus improve the overall SVR in genotypes 1 and 4 patients...
  12. doi request reprint Exploratory study of oral combination antiviral therapy for hepatitis C
    Fred Poordad
    University of Texas Health Science Center at San Antonio, Division of Gastroenterology and Nutrition MC7878, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA
    N Engl J Med 368:45-53. 2013
    ....
  13. doi request reprint Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Eric Lawitz
    The Texas Liver Institute, San Antonio, TX, USA
    Lancet Infect Dis 13:401-8. 2013
    ..We assessed the safety and efficacy of sofosbuvir, a uridine nucleotide analogue, in treatment-naive patients with genotype 1-3 HCV infection...
  14. pmc Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
    Eric Lawitz
    Texas Liver Institute, San Antonio, TX University of Texas Health Science Center, San Antonio, TX
    Hepatology 61:769-75. 2015
    ..One patient discontinued study treatment because of an adverse event and four patients experienced serious adverse events. The most common adverse events were influenza-like illness, fatigue, anemia, and neutropenia...
  15. doi request reprint Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
    Eric Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    Antiviral Res 89:238-45. 2011
    ..600 mg or placebo bid for 14 days was then co-administered with pegylated interferon alpha (PEG-IFN-α) administered on days 1 and 8 to genotype 1 relapsers...
  16. pmc Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection
    Eric Lawitz
    Alamo Medical Research, Ltd, San Antonio, TX, USA
    Antimicrob Agents Chemother 57:1209-17. 2013
    ..GS-9851 was generally well tolerated, with no notable differences in adverse event frequency across doses. The pharmacokinetic profile observed in this study was similar to that seen in a single-ascending-dose study in healthy subjects...
  17. doi request reprint Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA Electronic address
    Lancet 384:1756-65. 2014
    ..Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir...
  18. doi request reprint Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
    Eric Lawitz
    The Texas Liver Institute, University of Texas Health Science Center, 607 Camden, San Antonio, TX 78215, USA Electronic address
    J Infect 70:197-205. 2015
    ..To examine the safety and efficacy of ombitasvir and ABT-450 with ritonavir (ABT-450/r) ± ribavirin (RBV) in treatment-naïve, non-cirrhotic adults with chronic HCV genotype 1-3 infection...
  19. doi request reprint Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
    John M Vierling
    Baylor College of Medicine, Houston, TX, United States Electronic address
    J Hepatol 60:748-56. 2014
    ..We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin...
  20. doi request reprint Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA Electronic address
    Lancet 385:1075-86. 2015
    ....